HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $6 to $4.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $6 to $4.